Genetic Divergence of *Vibrio vulnificus* Clinical Isolates with Mild to Severe Outcomes

Kendall Kling,a Sonya A. Trinh,b Semen A. Leyn,c Dmitry A. Rodionov,d Ivan D. Rodionov,d Alfa Herrera,a Kasey Cervantes,a George Pankey,e Deborah Ashcraft,f Egon A. Ozer,a Adam Godzik,f Karla J. F. Satchellg

aDivision of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
bDivision of Infectious Diseases, Ochsner Medical Center, New Orleans, Louisiana, USA
cSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
dUniversity of California, San Diego, La Jolla, California, USA
eInfectious Disease Translational Research, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
fBiosciences Division, University of California Riverside School of Medicine, Riverside, California, USA
gDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

ABSTRACT The marine bacterium *Vibrio vulnificus* infects humans via food or water contamination, leading to serious manifestations, including gastroenteritis, wound infections, and septic shock. Previous studies suggest phylogenetic Lineage 1 isolates with the *vcgC* allele of the *vcg* gene cause human infections, whereas Lineage 2 isolates with the *vcgE* allele are less pathogenic. Mouse studies suggest that some variants of the primary toxin could drive more serious infections. A collection of 109 *V. vulnificus* United States human clinical isolates from 2001 to 2019 with paired clinical outcome data were assembled. The isolates underwent whole-genome sequencing, multilocus-sequence phylogenetic analysis, and toxinotype analysis of the multifunctional autoprocessing repeats-in-toxin (MARTX) toxin. In contrast to prior reports, clinical isolates were equally distributed between lineages. We found no correlation between phylogenetic lineage or MARTX toxinotype and disease severity. Infections caused by isolates in Lineage 1 demonstrated a borderline statistically significant higher mortality. Lineage 1 isolates had a trend toward a higher proportion of M-type MARTX toxins compared with Lineage 2, although this was not statistically significant.

IMPORTANCE *Vibrio vulnificus* is an aquatic pathogen that is capable of causing severe disease in humans. Previous studies have suggested that pathogenic isolates were restricted to certain phylogenetic lineages and possibly toxinotype. Our study demonstrated that phylogenetic lineage and multifunctional autoprocessing repeats-in-toxin (MARTX) toxinotype do not predict severity of infection. *V. vulnificus* strains capable of causing severe human disease are not concentrated in Lineage 1 but are genetically diverse. Thus, food surveillance based on lineage type or toxinotype may not be an appropriate intervention measure to control this rare but serious infection.

KEYWORDS *Vibrio vulnificus*, genome, phylogeny, toxin, surveillance, RTX toxins, patient outcome

*Vibrio vulnificus* is a Gram-negative halophilic bacterium that is part of the natural flora of warm coastal environments, but is also an opportunistic pathogen that causes life-threatening foodborne and wound infections worldwide (1). Foodborne infections occur after the ingestion of raw or undercooked seafood, particularly oysters, and result in illnesses ranging from a self-limited gastroenteritis to septicemia with rapid progression to multi-organ failure and death (2). Wound infections occur after seawater or seafood penetrates the skin layer and can spread to deeper structures, leading to necrotizing fasciitis requiring surgical debridement and even amputation.
(3). Several underlying medical conditions have been identified as risk factors for *V. vulnificus* infection, including chronic liver disease, diabetes mellitus, kidney disease, autoimmune disease, hematomatological disorders, and malignancy (4).

The incidence of *V. vulnificus* infections remains low despite the high proportion of patients at risk for infection and the widespread distribution of the pathogen in warm marine environments. Despite the fact that an estimated 19 to 27 million individuals are at risk for *V. vulnificus* infection, the incidence of reported infections is low, with the average number of cases in the United States at 120 per year (5). Raw oyster consumers account for 8% to 34% of the population, depending on the region, and oysters contain $10^3$ to $10^4$ CFU of *V. vulnificus* per gram during summer months (5). The discrepancy between the at-risk population and disease incidence suggests that either host factors or intrinsic bacterial factors contribute to disease severity. Identification of pathogenic strains in seafood harvests and coastal environments could reduce the incidence of *V. vulnificus* foodborne and wound infections.

Many studies have attempted to identify genetic markers that would predict which *V. vulnificus* strains can cause human disease with severe outcomes (6). Initially, strains were classified into three biotypes based on biochemical characteristics: Biotype 1 implicated in the majority of human infections, Biotype 2 primarily an eel pathogen, and Biotype 3 responsible for wound infections linked to tilapia contact in Israel (7). Additional studies have suggested specific determinants may distinguish pathogenic strains, including 165 rRNA, the pilF gene, and mannitol fermentation, but these characteristics also have been found among environmental strains (8, 9).

Multilocus sequence analysis (MLSA) of Biotype 1 strains revealed these strains split into two genetic lineages as predicted by the nucleotide sequence of the virulence-correlated gene (*vcg*), with clinical strains clustering in Lineage 1 (*vcgC*) and environmental strains represented in Lineage 2 (*vcgE*) (10). Sequence analysis of core genomes further identified a total of five lineages that did not correspond with the previously described biotypes, and found that most human clinical isolates clustered in Lineage 1 (11). As a result of these findings, rapid amplification methods to distinguish *vcgC* and *vcgE* alleles have been utilized in environmental and food safety research to monitor pathogenic *V. vulnificus* populations in coastal waters and harvests (12, 13).

However, there have been studies that challenge this dogma that isolates with potential to cause human disease would cluster in Lineage 1. A mouse model study of environmental and clinical strains found that isolates with the *vcgC* allele were more common in clinical strains and were more likely to cause severe infection and death, but isolates with the *vcgE* allele also were capable of causing lethal infections (14). Another mouse study utilized strains both from clinical and environmental sources and found no difference in virulence between *vcgC* and *vcgE* strains, although isolates obtained from colder temperature seasons were more virulent (15). Thus, despite many attempts to categorize *V. vulnificus*, the predictive value of genetic analysis, biochemical assays, and phylogeny to predict pathogenic potential remains unclear.

One difference that has also been suggested to predict virulence potential is the composition of the primary virulence toxin. The multifunctional autoprocessing repeats-in-toxin (MARTX) is the primary virulence factor for *V. vulnificus* infection in mouse models (16 to 19). The MARTX toxin forms pores in the eukaryotic cell plasma membrane and releases effector domain proteins into the cytoplasm, where they can perform a variety of cytotoxic activities, including necrosis, apoptosis, actin depolarization, activation of reactive oxygen species, and suppress the host immune response. (Fig. 1A) (20 to 23). Among *V. vulnificus* isolates, there are multiple MARTX toxin variants each with a unique repertoire of effector domains (24, 25) (Fig. 1B). Mouse models of *V. vulnificus* infection have suggested that overall virulence can be dependent upon the MARTX toxinotype, with C-type toxins more potent than M-type or B-type variants (24, 26, 27). However, it is unknown whether MARTX variants can explain the range of clinical presentations in human *V. vulnificus* infections.

Overall, it is unknown if severity of clinical disease correlates with phylogenetic lineage or MARTX type, as no prior studies have been performed that pair genome analysis with patient
outcome data. The objective of the study was to use whole-genome sequencing analysis of clinical *V. vulnificus* isolates with documented clinical outcomes to assess the relationships among *V. vulnificus* genetic background, MARTX variants, and infection severity.

**RESULTS**

**Cohort of U.S. *V. vulnificus* clinical isolates from 2001 to 2019 with paired patient and clinical outcomes data.** From 2007 through 2013, there were 114 *V. vulnificus* isolates submitted to the CDC that could be matched with Cholera and Other Vibrio Illness Surveillance (COVIS) reporting forms. Microbiological and genome-based identification revealed that several isolates were other species, including *Vibrio parahaemolyticus*, *Vibrio cholerae*, *Vibrio mimicus*, and *Aeromonas veronii*. Of the remaining 104 *V. vulnificus* isolates from the original batch, 73 passed quality control measures after whole-genome sequencing. From the second patient pool from 2001 to 2019, 42 isolates were obtained to increase the representation of Gulf States in the collection. Forty isolates were included in the collection as 2 were subsequently identified as other bacterial species and only 36 had corresponding clinical data. Clinical data without paired isolates were obtained for 2,413 suspected *V. vulnificus* cases from the same time period of 2001 to 2019.

Therefore, the isolate collection for this study comprised a total of 109 *V. vulnificus*
isolates with corresponding clinical data (Table S1). Patient characteristics were age, sex, liver disease, alcohol abuse, and presence of other comorbidities (cardiovascular disease, diabetes, renal disease, or malignancy). Infection type was characterized as either wound or gastrointestinal based on available clinical data.

The 109 sequenced isolates had no significant difference in patient characteristics compared to all reported cases for 2001 to 2019 (Table 1). Among the patients with a sequenced *V. vulnificus* isolate, the mean age was 59 years (range 5 to 87), and 93% were male. Alcoholism was reported in 27% of patients, and liver disease in 34% of patients. Gastrointestinal infections occurred in 39% of patients, and wound infection in 60%. Patients with adverse clinical outcomes include 11% requiring hospitalization for longer than 14 days, 14% with amputation, and 30% with death. The time to death ranged from 1 to 59 days. It appeared that rate of gastrointestinal versus wound infection type had a statistically significant difference; however, for 59% of all isolates reported to COVIS, a definitive source was not available or known. The isolates we sequenced had significantly more amputations and hospital stay greater than 14 days compared to all patients reported to COVIS, but there was no significant difference in mortality.

For all COVIS-reported cases from 2001 to 2019, the states with the highest prevalence of reported *V. vulnificus* infections were Florida, Texas, and Louisiana. Among reported cases with linked isolates from 2001 to 2019, the states with the most *V. vulnificus* infections included Louisiana, Texas, Georgia, and Maryland (Fig. 2).

We assembled a maximum likelihood phylogenetic tree of clinical isolates and reference genomes using the standardized 10-locus MLSA method of Bisharat et al. (28). The unrooted phylogenetic tree (Fig. 3) revealed the clinical isolates split into two distinct lineages. Reference genomes from prior studies were included to identify branches. These are referred to here as Lineage 1, also known as Clade 1 or Lineage C and previously closely linked with clinical isolates, and Lineage 2, also known as Clade 2 or Lineage E and closely linked with environmental isolates. PCR identification of the vcg gene allele in the first pool and analysis of DNA sequence in the second pool confirmed Lineage 1 isolates have the vcgC allele sequence while Lineage 2 carries the vcgE allele. No sequenced genomes from this collection clustered with Biotype 3 reference genomes VVby1 or BAA87, indicating our collection did not include any Biotype 3 isolates, consistent with these isolates being geographically restricted to Israel (7, 28).

**Severe disease outcome does not correlate with lineage.** Patient characteristics of Lineage 1 and Lineage 2 strains were compared (Table 2). There was no significant difference in gastrointestinal versus wound infections between the lineages. While there was no significant difference in hospitalization >14 days or amputation based on lineage, there was a borderline statistically significant higher mortality among patients with infections caused by Lineage 1 strains compared with Lineage 2 (36% versus 19%, P value = 0.05).

**MARTX variants.** The multifunctional autoprocessing repeats-in-toxin (MARTX) toxin is the primary virulence factor of *V. vulnificus*, is highly variable, and can rearrange by homologous recombination, with the M-type frequently arising from a C-type progenitor (24, 25) (Fig. 1). Among the 109 sequenced isolates, MARTX toxigenotypes included 54 C-type and 46 M-type. Rare toxigenotypes included four E-type, one D-type, and one type found to be shared with previously sequenced isolate FORC-009 and herein referred to as F-type (Table 3). Three of the strains had incomplete toxin genes, and thus the toxigenotype could not be assigned. Fig. 4 depicts toxigenotype along the phylogenetic tree in the inner ring. Both C- and M-type toxins are found in both Lineages 1 and 2. There was a relative preponderance of type M toxin in Lineage 1 strains, although this was not statistically significant. All four E-type toxins occurred only in Lineage 2 and were from wound infection isolates.

Of patients with a C- or M-type toxin, 44% had a severe outcome, although there was no statistically significant difference in any adverse outcome based on toxigenotype (Table 3). One patient with an E-type toxin had a severe outcome. Neither patient with a strain producing the F- or D-type toxin had a severe outcome.

**DISCUSSION**

*Vibrio vulnificus* is a Gram-negative halophilic bacterium that is part of the natural flora of warm coastal environments but is also an opportunistic human pathogen...
TABLE 1  Patient characteristics, clinical presentation, and outcomes associated with sequenced *V. vulnificus* isolates compared to all *V. vulnificus* infections reported to COVIS from 2001 through 2019

| Demographic information | Isolates with paired clinical data (n = 109) | Total reported to COVIS (n = 2,431) | P value |
|-------------------------|---------------------------------------------|-------------------------------------|---------|
| Patient characteristics  |                                            |                                     |         |
| Age, yrs [avg (range)]  | 59 (5–87)                                   | 60 (0–100)                          | 0.68    |
| Male (%)                | 101 (93)                                     | 2,038 (84)                          | 0.32    |
| Liver disease           | 37 (34)                                      | 680 (28)                            | 0.23    |
| Alcohol                 | 29 (27)                                      | 583 (24)                            | 0.56    |
| Other comorbidities     | 70 (64)                                      | 1,681 (69)                          | 0.56    |
| State (n)               | Louisiana (33)                               | Florida (577)                       |         |
|                         | Texas (27)                                   | Texas (430)                         |         |
|                         | Georgia (12)                                 | Louisiana (233)                     |         |
|                         | Maryland (11)                                | Maryland (170)                      |         |
|                         | Tennessee (5)                                | Virginia (144)                      |         |
|                         | North Carolina (4)                           | Alabama (101)                       |         |
|                         | Virginia (4)                                 | Georgia (96)                        |         |
|                         | Hawaii (3)                                   | North Carolina (91)                 |         |
|                         | Arizona (2)                                  | Mississippi (85)                    |         |
|                         | Florida (2)                                  | Hawaii (68)                         |         |
|                         | Alabama (1)                                  | California (62)                     |         |
|                         | Connecticut (1)                              | Tennessee (45)                      |         |
|                         | Illinois (1)                                 | New Jersey (43)                     |         |
|                         | Massachusetts (1)                            | New York (42)                       |         |
|                         | Ohio (1)                                     | South Carolina (38)                 |         |
|                         | Rhode Island (1)                             | Arizona (24)                        |         |
|                         |                                               | Pennsylvania (17)                   |         |
|                         |                                               | Colorado (14)                       |         |
|                         |                                               | Connecticut (12)                    |         |
|                         |                                               | Massachusetts (12)                  |         |
|                         |                                               | Michigan (12)                       |         |
|                         |                                               | Oklahoma (12)                       |         |
|                         |                                               | Delaware (10)                       |         |
|                         |                                               | Indiana (8)                         |         |
|                         |                                               | Kentucky (8)                        |         |
|                         |                                               | Ohio (8)                            |         |
|                         |                                               | Illinois (7)                        |         |
|                         |                                               | District of Columbia (6)            |         |
|                         |                                               | Minnesota (6)                       |         |
|                         |                                               | New Mexico (6)                      |         |
|                         |                                               | Rhode Island (6)                    |         |
|                         |                                               | Maine (5)                           |         |
|                         |                                               | Arkansas (4)                        |         |
|                         |                                               | Kansas (4)                          |         |
|                         |                                               | Missouri (4)                        |         |
|                         |                                               | Washington (4)                      |         |
|                         |                                               | Nevada (3)                          |         |
|                         |                                               | Oregon (3)                          |         |
|                         |                                               | Wisconsin (3)                       |         |
|                         |                                               | New Hampshire (2)                   |         |
|                         |                                               | Utah (2)                            |         |
|                         |                                               | Guam (1)                            |         |
|                         |                                               | Nebraska (1)                        |         |
|                         |                                               | North Dakota (1)                    |         |
|                         |                                               | Vermont (1)                         |         |

| Infection type          |                                            |                                     |         |
|-------------------------|---------------------------------------------|-------------------------------------|---------|
| Gastrointestinal (%)    | 42 (39)                                     | 547 (23)                            | 0.00006 |
| Wound (%)               | 65 (60)                                     | 870 (36)                            | 0.000003|
| Other or unknown (%)    | 2 (1)                                       | 1,014 (42)                          |         |

| Outcomes                |                                            |                                     |         |
|-------------------------|---------------------------------------------|-------------------------------------|---------|
| Hospitalization >14 days (%) | 12 (11)                                   | 145 (6)                             | 0.03    |
| Amputation              | 15 (14)                                     | 126 (5)                             | 0.00004 |
| Death                   | 33 (30)                                     | 590 (24)                            | 0.18    |
| Time to death, days (range) | 1–59                                       | 0–123                               |         |
acquired via ingestion or water exposure leading to a broad range of clinical manifestations, including gastroenteritis, wound infections, and septic shock. Given the overall low prevalence of this infection, studies have been done to identify pathogenic determinants given the high number of humans at risk. In the present study, we assembled the first isolate collection for *V. vulnificus* with paired clinical data. In total, 109 clinical isolates from across the United States underwent genomic extraction, phylogenetic analysis, and identification of MARTX toxin type. Despite earlier studies suggesting the majority of clinical isolates arise from Lineage 1, we found roughly equal distribution of infections between Lineage 1 and 2. We found a borderline statistically significant higher mortality rate in Lineage 1 isolates. This suggests that the earlier studies may have been biased to predominantly include clinical isolates from patients who had died from their infection, and thus the isolates were more likely to be preserved. However, this is only speculation as all prior studies on phylogeny of *V. vulnificus* have not included paired analysis of patient outcomes.

Previous studies also have suggested that the strains that secrete the C-type MARTX toxin are more virulent in mice (24, 27). Thus, it was hypothesized that C-type toxin could be associated with more severe patient outcomes. However, we found that C-type and M-type toxins were most frequently present in the clinical isolates but that the MARTX toxin variant type was not predictive of disease severity. Less severe outcomes were associated with E-, F-, and D-type toxins, although these cases are rare in our collection, and thus definitive conclusions regarding disease severity correlation would require a substantially larger collection. If further studies suggest that C-type or M-type toxins are more likely to cause severe disease, public health surveillance programs could potentially use these markers for environmental screening.

Furthermore, a recent study using *V. vulnificus* infection of mice showed no correlation of virulence to genotype or biochemical assays (9). Our data are also in support of a recent paper that showed no correlation of genotype or standard biochemical assays used to identify bacteria in the clinical setting with virulence potential in mice (15). One recent study has suggested that bacteria might be differentiated by ecotype. This study suggested that strains from the C1 ecotype, which readily degraded a variety of carbohydrates (designated as bloomers), could be more highly virulent (29). A major advantage of our study is that the collection of stains assembled with paired outcome data could be used to further test this possibility as well as other factors that could link growth characteristics with virulence.

Overall, our study of clinical isolates reveals that *V. vulnificus* from both major phylogenetic lineages are capable of causing severe disease in humans. Of importance for
public health surveillance, these data suggest that PCR and sequence-based monitoring of the vcg allele to distinguish vcgC or vcgE or any other method based on distinguishing the two primary lineages in the environment or seafood are not likely to be sufficient to prevent the incidence of severe infections in humans.

MATERIALS AND METHODS

Bacterial isolates and identification. The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) established the Cholera and Other Vibrio Illness Surveillance (COVIS), a national passive surveillance system to monitor the incidence of Vibrio infections in the United States (30). All data for this study were de-identified to remove patient identifiers before being released from Ochsner or the CDC. The project was reviewed by the Northwestern University Institution Review Board and declared exempt.

The first pool of bacterial isolates we obtained for this study comprised 73 clinical V. vulniﬁcus isolates with linked clinical information. These isolates were provided to the CDC between January 2007 and December 2013 as part of COVIS. All isolates in this pool were given the designation “NUST#.”

The second pool comprised 40 clinical isolates from the CDC (designated “NUKK#”) or from Ochsner Medical Center (designated “OMC#”), although only 36 had corresponding clinical data sufﬁcient for this analysis. Isolates in the second pool were from an expanded time frame between 2001 and 2019 and were speciﬁcally selected to increase representation of isolates from Gulf Coast states. In total, we collected 109 isolates that had corresponding clinical data (Table S1, supplemental data set). All isolates were identiﬁed to the species level using two culture methods; V. vulniﬁcus colonies grew as yellow or green on Thiosulfate Citrate Bile Salts Sucrose (TCBS) agar (BD, Franklin Lakes, NJ) and green-blue or turquoise-blue on CHROMagar Vibrio (Paris, France). PCR ampliﬁcation to conﬁrm the vcg allele was done for the ﬁrst pool according to the methods of Rosche et al. (10). The second pool vcg alleles were assigned from the vcg gene sequence extracted from whole-genome sequencing (10). Final veriﬁcation

FIG 3 Unrooted MLSA phylogenetic tree of clinical isolates of V. vulniﬁcus with reference isolates. Maximum likelihood phylogeny of concatenated DNA sequences for 10 housekeeping genes extracted from whole-genome sequences according to the standard MLSA method of Bisharat et al. (29). MLSA sequences for representative isolates obtained from the PubMLST database (highlighted in yellow) were used to identify Lineages 1 and 2 and sublineages. Diagram was generated in iTOL (42).
of species of the second pool was identified from the whole-genome sequence using ribosomal multilocus sequence typing at https://pubmlst.org/species-id (31).

COVIS data were also obtained from the CDC for a total of 2,431 reported V. vulnificus cases from 2001 to 2019, and data were analyzed alongside the data from isolates with paired clinical data.

DNA extraction. Bacterial isolates stored at −280°C were plated on Luria-Bertani (LB) agar and cultured overnight at 37°C. Single colonies were inoculated in LB broth and grown overnight at 37°C with shaking. Genomic DNA was extracted from broth cultures using the Promega Maxwell 16 Cell DNA purification kit (Madison, WI) according to manufacturer’s protocol. Genomic DNA extracts were stored at −280°C.

Whole-genome sequencing and assembly. For the first pool of isolates, genomic DNA libraries were prepared using the Illumina Nextera XT DNA Library Preparation kit (San Diego, CA). DNA library concentrations were quantified using the Quant-iT dsDNA High-Sensitivity assay kit (Life Technologies, Grand Island, NY). Equal amounts of each library (200 ng) were pooled and sequenced on the Illumina HiSeq 4000 system to generate 150-bp paired-end reads. For the first pool of isolates, sequencing was performed at the University of Maryland School of Medicine Institute for Genome Sciences, Baltimore, MD. Raw sequencing reads were assembled de novo using SPAdes v3.10.0 (32) as implemented at the Pathosystems Resource Integration Center (PATRIC) Bioinformatics Resource Center (33) and annotated using the PATRIC RASTtk-enabled Genome Annotation Service (34). For the second pool of isolates, genomic DNA was submitted for 150-Mbp Illumina whole-genome sequencing at the Microbial Genome Sequencing Center (MiGS) in Pittsburgh, Pennsylvania. Species assignment was verified from sequence reads using kraken v1.0 and the minikraken 8GB database (35). Adapter trimming and quality filtering of sequencing reads was performed using Trimmomatic v0.36 (36). Assembly was performed with SPAdes v3.9.1 (32), and assemblies were filtered to remove contigs shorter than 200 bp and with less than 5× average read coverage. We deposited the genomes into GenBank under NCBI BioProject accession no. PRJNA813597. A BioSample was created for each strain with accession numbers SAMN26511979 to SAMN26512087.

MLSA. Partial gene sequences for the standardized Vibrio vulnificus 10-locus MLSA method for glp, gyrB, mdh, metG, purM, dtnA, lysA, pntA, pyrC, and tnaA were extracted from sequenced genomes. MLSA data for reference genomes were selected from 473 isolates available online at https://pubmlst.org/vvulnificus/ based on representative positioning on the phylogenetic tree publicly available at http://ncbi.nlm.nih.gov/genome/189. MLSA allele sequences from each isolate were concatenated and aligned using mafft v7.36 (36). Assembly was performed with SPAdes v3.9.1 (32), and assemblies were filtered to remove contigs shorter than 200 bp and with less than 5× average read coverage. We deposited the genomes into GenBank under NCBI BioProject accession no. PRJNA813597. A BioSample was created for each strain with accession numbers SAMN26511979 to SAMN26512087.

MLSA allele sequences from each isolate were concatenated and aligned using mafft v7.36 (36). Assembly was performed with SPAdes v3.9.1 (32), and assemblies were filtered to remove contigs shorter than 200 bp and with less than 5× average read coverage. We deposited the genomes into GenBank under NCBI BioProject accession no. PRJNA813597. A BioSample was created for each strain with accession numbers SAMN26511979 to SAMN26512087.

### TABLE 2

| Characteristic                      | Lineage 1 strains (n = 61) | Lineage 2 strains (n = 48) | P value |
|-----------------------------------|---------------------------|---------------------------|---------|
| Patient characteristics           |                           |                           |         |
| Age, yrs (avg, range)             | 61 (12–86)                | 55 (5–87)                 | 0.49    |
| Male (n, %)                       | 52 (85)                   | 44 (92)                   | 0.64    |
| Infection (n, %)                  |                           |                           |         |
| Gastrointestinal                  | 25 (41)                   | 13 (27)                   | 0.12    |
| Wound                             | 29 (48)                   | 28 (58)                   | 0.30    |
| Unspecified                       | 7 (11)                    | 7 (15)                    | 0.37    |
| Severity (n, %)                   |                           |                           |         |
| Hospitalization >14 days          | 6 (10)                    | 6 (13)                    | 0.65    |
| Amputation                        | 7 (11)                    | 7 (15)                    | 0.37    |
| Death                             | 22 (36)                   | 9 (19)                    | 0.05    |
| Time to death, days (range)       | 1–59                      | 2–39                      |         |
| MLSA type (n, %)                  |                           |                           |         |
| C                                 | 27 (44)                   | 27 (56)                   | 0.19    |
| M                                 | 32 (52)                   | 14 (29)                   | 0.03    |
| E                                 | 0                         | 4 (8)                     | NAa     |
| D                                 | 1 (2)                     | 0                         | NA      |
| F                                 | 0                         | 1 (2)                     | NA      |

*NA, not applicable.

### TABLE 3

| Patient Outcomes                      | C (n = 54) | M (n = 46) | P value (C vs M) | F (FORC) (n = 1) | E (n = 4) | D (n = 1) | Truncated (n = 3) |
|---------------------------------------|------------|------------|-----------------|-----------------|-----------|-----------|------------------|
| Severe Outcome (n, %)                 | 22 (40)    | 22 (46)    | 0.35            | 0               | 1 (25)    | 0         | 1                |
| Hospitalization >14 days              | 7 (13)     | 4 (9)      | 0.41            | 0               | 0         | 0         | 1 (33)           |
| Amputation                            | 7 (13)     | 6 (13)     | 1               | 0               | 1 (25)    | 0         | 0                |
| Death                                 | 15 (28)    | 16 (35)    | 0.41            | 0               | 0         | 0         | 0                |
| Time to death (days)                  | 1–39       | 1–59       |                 |                 |           |           |                  |
estimate the best-fit nucleotide substitution model by means of Bayesian information criterion (BIC) (38, 39). Tree topology was assessed both with the Shimodaira-Hasegawa approximate likelihood ratio test (SH-aLRT) and with the ultrafast bootstrap (UFboot) with 1,000 replicates each (40, 41). Phylogenetic tree was visualized and annotated using the Interactive Tree of Life (iTOL) (42).

Clinical analysis. Patient characteristics, clinical presentation, and outcomes were analyzed for all infections reported to COVIS from 2001 through 2019. Severity of infection was categorized as follows: Category 1 was “mild” with recovery; Category 2 was “severe,” defined as requiring hospitalization for >14 days and/or amputation; and Category 3 was death. The unpaired t test was used to compare means, and chi-squared analysis was performed to compare proportions using Microsoft Excel.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

TABLE S1, XLSX file, 0.02 MB.
ACKNOWLEDGMENTS

We thank the CDC for providing strains, with special thanks to Cheryl Tan, Anna Newton, Erin Stokes, and Michael Hughes for providing COVIS data and pairing available clinical data with isolates. Thanks to Fiorella Krapp-Lopez and Katherine Murphy for assistance with sequencing library preparation. We thank the University of Maryland Institute for Genome Sciences and the Microbial Genome Sequencing Center (MiGS) for whole-genome sequencing services. We thank the BV-BRC, particularly Allan Dickerman, for genome assembly assistance and for use of resources at Patrickbrc.org, which is funded by NIH Contract No. HHSN27220140027C to Rick Stevens of the University of Chicago.

K.J.F.S. has a significant financial interest in Situ Biosciences, a contract research organization that conducts studies unrelated to this work. All other authors declare no conflicts of interest.

This work was supported by a Ruth L. Kirschstein National Research Service Award in Translational Research in Infectious Diseases T32AI095927 (to S.A.T.) and National Institutes of Health grants R01AI092825 and R01AI098369 (to K.J.F.S.).

This work was publicly presented at the 19th Annual Microbial Sciences Symposium (Harvard University, Cambridge, MA, 30 April 2022) and the 1st Annual Pathogen Genomics Symposium (Northwestern University, Chicago, IL, 4 May 2022).

REFERENCES

1. Huang KC, Weng HT, Yang TY, Chang TS, Huang TW, Lee MS. 2016. Distribution of fatal Vibrio vulniﬁcus necrotizing skin and soft-tissue infections: a systematic review and meta-analysis. Medicine (Baltimore) 95:e2627. https://doi.org/10.1097/MD.0000000000002627.

2. Zhao H, Xu L, Dong H, Hu J, Gao H, Yang M, Zhang X, Chen X, Fan J, Ma W. 2015. Correlations between clinical features and mortality in patients with Vibrio vulniﬁcus infection. PLoS One 10:e0136019. https://doi.org/10.1371/journal.pone.0136019.

3. Matsumoto K, Ohshige K, Fujita N, Tomita Y, Mitsumizo S, Nakashima M, Oishi H. 2010. Clinical features of Vibrio vulniﬁcus infections in the coastal areas of the Ariake Sea, Japan. J Infect Chemother 16:272–279. https://doi.org/10.1007/s10156-010-0050-z.

4. Menon MP, Yu PA, Iwamoto M, Painter J. 2013. Pre-existing medical conditions associated with Vibrio vulniﬁcus septicaemia. Epidemiol Infect 142: 878–881.

5. Warner E, Oliver JD. 2008. Population structures of two genotypes of Vibrio vulniﬁcus in oysters (Crassostrea virginica) and seawater. Appl Environ Microbiol 74:840–85. https://doi.org/10.1128/AEM.01434-07.

6. Phillips KE, Satchell KJ. 2017. Vibrio vulniﬁcus: from oyster colonist to human pathogen. PLoS Pathog 13:e1006053. https://doi.org/10.1371/journal.ppat.1006053.

7. Bisharat N, Agmon V, Finkelstein R, Raz R, Ben-Dror G, Lerner L, Soboh S, Colodner R, Cameron DN, Wykstra DL, Swerdlow DL, Farmer JJ, III, Israel Vibrio Study Group. 1999. Clinical, epidemiological, and microbiological features of Vibrio vulniﬁcus biogroup 3 causing outbreaks of wound infection and bacteremia in Israel. Lancet 354:1421–1424. https://doi.org/10.1016/S0140-6736(99)02471-X.

8. Gulig PA, de Crecy-Lagard V, Wright AC, Walts B, Telonis-Scott M, McIntyre LM. 2010. SOLiD sequencing of four Vibrio vulniﬁcus genomes enables comparative genomic analysis and identiﬁcation of candidate clade-speciﬁc virulence genes. BMC Genomics 11:512. https://doi.org/10.1186/1471-2164-11-512.

9. Bier N, Bechhals S, Diescher S, Klein F, Hauk G, Dutty O, Strauch E, Diez-Martin R, 2013. Genotypic diversity and virulence characteristics of clinical and environmental Vibrio vulniﬁcus isolates from the Baltic Sea region. Appl Environ Microbiol 79:3570–3581. https://doi.org/10.1128/AEM.00477-13.

10. Rosche TM, Yano Y, Oliver JD. 2005. A rapid and simple PCR analysis indicates there are two subgroups of Vibrio vulniﬁcus which correlate with clinical or environmental isolation. Microbiol Immunol 49:381–389. https://doi.org/10.1111/j.1348-0421.2005.b03731.x.

11. Roig FJ, Gonzalez-Candelas F, Sanjuan E, Fouz B, Fei EI, Llorens C, Baker-Austin C, Oliver JD, Danin-Poleg Y, Gibas CJ, Kashi Y, Gulig PA, Morrison SS, Amaro C. 2017. Phylogeny of Vibrio vulniﬁcus from the analysis of the core-genome: implications for intra-species taxonomy. Front Microbiol 8: 2613. https://doi.org/10.3389/fmicb.2017.02613.

12. Williams TC, Froelich BA, Phippen B, Fowler P, Noble RT, Oliver JD. 2017. Different abundance and correlational patterns exist between total and presumed pathogenic Vibrio vulniﬁcus and V. para-haemolyticus in shellﬁsh and waters along the North Carolina coast. FEMS Microbiol Ecol 93:e0071.

13. Han F, Wang F, Ge B. 2011. Detecting potentially virulent Vibrio vulniﬁcus strains in raw oysters by quantitative loop-mediated isothermal ampliﬁcation. Appl Environ Microbiol 77:2589–2595. https://doi.org/10.1128/AEM.02992-10.

14. Thiaville PC, Bourdage KL, Wright AC, Farrell-Evans M, Garvan CW, Gulig PA. 2011. Genotype is correlated with but does not predict virulence of Vibrio vulniﬁcus biotype 1 in subcutaneously inoculated, iron dextran-treated mice. Infect Immun 79:1194–1207. https://doi.org/10.1128/IAI.00130-10.

15. Lydon KA, Kinsey T, Le C, Gulig PA, Jones JL. 2021. Biochemical and virulence characterization of Vibrio vulniﬁcus isolates from clinical and environmental sources. Front Cell Infect Microbiol 11:637019. https://doi.org/10.3389/fcimm.2021.637019.

16. Jeong HG, Satchell KJ. 2012. Additive function of Vibrio vulniﬁcus MARTXxv and VvhA cytolsins promotes rapid growth and epithelial tissue necrosis during intestinal infection. PLoS Pathog 8:e1002581. https://doi.org/10.1371/journal.ppat.1002581.

17. Liu M, Alice AF, Naka H, Cross HJ. 2007. The HlyU protein is a positive regulator of rtxA, a gene responsible for cytotoxicity and virulence in the human pathogen Vibrio vulniﬁcus. Infect Immun 75:3282–3289. https://doi.org/10.1128/IAI.00405-07.

18. Kim YR, Lee SE, Kook H, Yeom JA, Kim SY, Chung SS, Choy HE, Rhode JH. 2008. Vibrio vulniﬁcus RTX toxin kills host cells only after contact of the bacteria with host cells. Cell Microbiol 10:848–862. https://doi.org/10.1111/j.1462-5822.2007.01088.x.

19. Lee JH, Kim MW, Kim BS, Kim SM, Lee BC, Kim TS, Choi SH. 2007. Identiﬁcation and characterization of the Vibrio vulniﬁcus rtxA essential for cytotoxicity in vitro and virulence in mice. J. Microbiol 45:146–52. https://pubmed.ncbi.nlm.nih.gov/17483800/.

20. Woida PJ, Satchell KJF. 2020. The Vibrio cholerae MARTX toxin silences the inflammatory response to cytoskeletal damage before inducing actin cytoskeleton collapse. Sci Signal 13:esa94947. https://doi.org/10.1126/scisignal.esa94947.

21. Woida PJ, Kitts G, Shee S, Godzik A, Satchell KJ. 2022. Actin cross-linking effector domain of the Vibrio vulniﬁcus F-type MARTX Toxin dominates disease progression during intestinal infection. Infect Immun 90:e00627-21. https://doi.org/10.1128/iai.00627-21.

22. Woida PJ, Satchell KJF. 2018. Coordinated delivery and function of bacterial MARTX toxin effectors. Mol Microbiol 107:133–141. https://doi.org/10.1111/mmi.13875.

23. Kim BS. 2018. The modes of action of MARTX toxin effector domains. Toxins (Basel) 10:507. https://doi.org/10.3390/toxins1020507.

24. Kwak JS, Jeong HG, Satchell KJ. 2011. Vibrio vulniﬁcus rtxA gene recombination generates toxin variants with altered potency during intestinal infection.
V. vulniﬁcus Clinical Isolate Phylogeny

infection. Proc Natl Acad Sci U S A 108:1645–1650. https://doi.org/10.1073/pnas.1014391.108

25. Roig FJ, Gonzalez-Candelas F, Amaro C. 2011. Domain organization and evolution of multifunctional autoprocessing repeats-in-toxin (MARTX) toxin in Vibrio vulniﬁcus. Appl Environ Microbiol 77:657–668. https://doi.org/10.1128/AEM.01806-10

26. Gavin HE, Satchell KJF. 2019. RRSP and RID effector domains dominate the virulence impact of Vibrio vulniﬁcus MARTX toxin. J Infect Dis 219:889–897. https://doi.org/10.1093/infdis/jiy980

27. Kim BS, Gavin HE, Satchell KJF. 2017. Variable virulence of biotype 3 Vibrio vulniﬁcus due to MARTX effector domain composition. mSphere 2:e00272. https://doi.org/10.1128/mSphereDirect.00272-17

28. Bisharat N, Cohen DJ, Maiden MC, Crook DW, Peto T, Harding RM. 2007. The evolution of genetic structure in the marine pathogen, Vibrio vulniﬁcus. Infect Genet Evol 7:685–693. https://doi.org/10.1016/j.meegid.2007.07.007

29. Lopez-Perez M, Jayakumar JM, Haro-Moreno JM, Zaragoza-Solas A, Reddi G, Rodriguez-Valera F, Shapiro OH, Alam M, Almagro-Moreno S. 2019. Evolutionary model of cluster divergence of the emergent marine pathogen Vibrio vulniﬁcus: from genotype to ecotype. mBio 10:e02852-18. https://doi.org/10.1128/mBio.02852-18

30. Newton A, Kendall M, Vugia DJ, Henao OL, Mahon BE. 2012. Increasing rates of vibriosis in the United States, 1996–2010: review of surveillance data from 2 systems. Clin Infect Dis 54(Suppl 5):S391–S395. https://doi.org/10.1093/cid/cis243

31. Jolley KA, Bliss CM, Bennett JS, Bratcher HB, Brehony C, Colles FM, Wimalaratna H, Harrison OB, Sheppard SK, Cody AJ, Maiden MCJ. 2012. Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain. Microbiology (Reading) 158:1005–1015. https://doi.org/10.1099/mic.0.05549-0

32. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021

33. Wattam AR, Davis JJ, Assaf R, Boisvert S, Brettin T, Bun C, Conrad N, Dietrich EM, Disz T, Gabbard JL, Gerdes S, Henry CS, Kenyon RW, Mach D, Mao C, Nordberg EK, Olsen GJ, Murphy-Olson DE, Olson R, Overbeek R, Parrello B, Pushch GD, Shukla M, Vonstein V, Warren A, Xia F, Yoo H, Stevens RL. 2017. Improvements to PATRIC, the all-bacterial Bioinformatics Database and Analysis Resource Center. Nucleic Acids Res 45:D35–D542. https://doi.org/10.1093/nar/gkw1017

34. Brettin T, Davis JJ, Disz T, Edwards RA, Gerdes S, Olsen GJ, Olson R, Overbeek R, Parrello B, Pushch GD, Shukla M, Thomason JA, III, Stevens R, Vonstein V, Wattam AR, Xia F. 2015. RASTK: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci Rep 5:8365. https://doi.org/10.1038/srep08365

35. Wood DE, Salzberg SL. 2014. Kraken: ultrafast metagenomic sequence classiﬁcation using exact alignments. Genome Biol 15:R46. https://doi.org/10.1186/gb-2014-15-3-46

36. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a ﬂexible trimmer for illumina sequence data. Bioinformatics 30:2114–2120. https://doi.org/10.1093/bioinformatics/btu170

37. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780. https://doi.org/10.1093/molbev/mst10

38. Kalyaanamoorthy S, Minh BQ, von Haeseler A, Jermiin LS. 2017. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods 14:587–589. https://doi.org/10.1038/nmeth.4285

39. Minh BQ, Schmidt HA, Chenomor O, Schrempf D, Woodhams MD, von Haeseler A, Lanfear R. 2020. IQ-TREE 2: new models and efﬁcient methods for phylogenetic inference in the genomic era. Mol Biol Evol 37:1530–1534. https://doi.org/10.1093/molbev/msaa015

40. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59:307–312. https://doi.org/10.1093/sysbio/syp010

41. Hoang DT, Chenomor O, von Haeseler A, Minh BQ, Vinh LS. 2018. UFBoot2: Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol 35:518–522. https://doi.org/10.1093/molbev/msx281

42. Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. Nucleic Acids Res 47:W256–W259. https://doi.org/10.1093/nar/gkz239

43. Gavin HE, Satchell KJ. 2015. MARTX toxins as effector delivery platforms. Pathog Dis 73:ftv092. https://doi.org/10.1093/femspd/ftv092